Search Page

1

Cite

Share

How common is truly benign MS in a UK population?

Tallantyre EC, Major PC, Atherton MJ, Davies WA, Joseph F, Tomassini V, Pickersgill TP, Harding KE, Willis MD, Winter M, Robertson NP. Tallantyre EC, et al. Among authors: pickersgill tp. J Neurol Neurosurg Psychiatry. 2019 May;90(5):522-528. doi: 10.1136/jnnp-2018-318802. Epub 2018 Sep 3. J Neurol Neurosurg Psychiatry. 2019. PMID: 30177509 Free PMC article.

Cite

Share

2

Cite

Share

Alemtuzumab-induced remission of multiple sclerosis-associated uveitis.

Willis MD, Pickersgill TP, Robertson NP, Lee RWJ, Dick AD, Carreño E. Willis MD, et al. Among authors: pickersgill tp. Int Ophthalmol. 2017 Oct;37(5):1229-1233. doi: 10.1007/s10792-016-0370-9. Epub 2016 Oct 11. Int Ophthalmol. 2017. PMID: 27730316

Cite

Share

3

Cite

Share

Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosis.

Beesley R, Anderson V, Harding KE, Joseph F, Tomassini V, Pickersgill TP, Robertson NP, Tallantyre EC. Beesley R, et al. Among authors: pickersgill tp. Mult Scler. 2018 Nov;24(13):1786-1787. doi: 10.1177/1352458518778007. Epub 2018 May 15. Mult Scler. 2018. PMID: 29762077 No abstract available.

Cite

Share

4

Cite

Share

Multiple sclerosis relapses and depression.

Moore P, Hirst C, Harding KE, Clarkson H, Pickersgill TP, Robertson NP. Moore P, et al. Among authors: pickersgill tp. J Psychosom Res. 2012 Oct;73(4):272-6. doi: 10.1016/j.jpsychores.2012.08.004. Epub 2012 Sep 11. J Psychosom Res. 2012. PMID: 22980532

Cite

Share

5

Cite

Share

Site-specific clinical disease onset in multiple sclerosis.

Willis MD, Harding KE, Wardle M, Pickersgill TP, Tomassini V, Loveless S, Robertson NP. Willis MD, et al. Among authors: pickersgill tp. Eur J Neurol. 2015 Apr;22(4):732-5. doi: 10.1111/ene.12564. Epub 2014 Sep 8. Eur J Neurol. 2015. PMID: 25196326

Cite

Share

6

Cite

Share

Multiple sclerosis: long-term outcomes in ethnic minorities. Analysis of a UK population-based registry.

Alsaeed MO, Harding KE, Williams OH, Willis MD, Hrastelj J, Tallantyre EC, Joseph FG, Wardle M, Pickersgill TP, Robertson NP. Alsaeed MO, et al. Among authors: pickersgill tp. Eur J Neurol. 2018 Apr;25(4):701-704. doi: 10.1111/ene.13571. Epub 2018 Feb 16. Eur J Neurol. 2018. PMID: 29338105

Cite

Share

7

Cite

Share

Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.

Willis MD, Harding KE, Pickersgill TP, Wardle M, Pearson OR, Scolding NJ, Smee J, Robertson NP. Willis MD, et al. Among authors: pickersgill tp. Mult Scler. 2016 Aug;22(9):1215-23. doi: 10.1177/1352458515614092. Epub 2015 Oct 29. Mult Scler. 2016. PMID: 26514979

Cite

Share

8

Cite

Share

Long-term outcome of paediatric-onset multiple sclerosis: a population-based study.

Harding KE, Liang K, Cossburn MD, Ingram G, Hirst CL, Pickersgill TP, Te Water Naude J, Wardle M, Ben-Shlomo Y, Robertson NP. Harding KE, et al. Among authors: pickersgill tp. J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):141-7. doi: 10.1136/jnnp-2012-303996. Epub 2012 Nov 15. J Neurol Neurosurg Psychiatry. 2013. PMID: 23154123

Cite

Share

9

Cite

Share

Demographic and clinical factors associated with changes in employment in multiple sclerosis.

Moore P, Harding KE, Clarkson H, Pickersgill TP, Wardle M, Robertson NP. Moore P, et al. Among authors: pickersgill tp. Mult Scler. 2013 Oct;19(12):1647-54. doi: 10.1177/1352458513481396. Epub 2013 May 7. Mult Scler. 2013. PMID: 23652213

Cite

Share

10

Cite

Share

Systemic complement profiling in multiple sclerosis as a biomarker of disease state.

Ingram G, Hakobyan S, Hirst CL, Harris CL, Loveless S, Mitchell JP, Pickersgill TP, Robertson NP, Morgan BP. Ingram G, et al. Among authors: pickersgill tp. Mult Scler. 2012 Oct;18(10):1401-11. doi: 10.1177/1352458512438238. Epub 2012 Feb 21. Mult Scler. 2012. PMID: 22354735 Free PMC article.

Cite

Share